The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
Researchers are reporting progress on the path to a "universal" flu vaccine -- one that would battle all strains of the virus and give the world a weapon against future flu pandemics.
